Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6222025 | KASTLE THERAPS LLC | Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom |
Mar, 2015
(9 years ago) | |
US5914396 | KASTLE THERAPS LLC | 2'-O-modified nucleosides and phosphoramidites |
Jun, 2016
(7 years ago) | |
US6451991 | KASTLE THERAPS LLC | Sugar-modified gapped oligonucleotides |
Feb, 2017
(7 years ago) | |
US6166197 | KASTLE THERAPS LLC | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions |
Dec, 2017
(6 years ago) | |
US7015315 | KASTLE THERAPS LLC | Gapped oligonucleotides |
Mar, 2023
(1 year, 1 month ago) | |
US7101993 | KASTLE THERAPS LLC | Oligonucleotides containing 2′-O-modified purines |
Sep, 2023
(7 months ago) | |
US7511131 | KASTLE THERAPS LLC | Antisense modulation of apolipoprotein B expression |
Jan, 2027
(2 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7407943 | KASTLE THERAPS LLC | Antisense modulation of apolipoprotein B expression |
Aug, 2021
(2 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-41) | Jan 29, 2020 |
Orphan Drug Exclusivity(ODE) | Jan 29, 2020 |
New Chemical Entity Exclusivity(NCE) | Jan 29, 2018 |
Drugs and Companies using MIPOMERSEN SODIUM ingredient
NCE-1 date: 29 January, 2017
Market Authorisation Date: 29 January, 2013
Treatment: Adjunctive therapy to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol, apolipoprotein b, total cholesterol, and non-high density lipoprotein cholesterol in pts with h...
Dosage: SOLUTION;SUBCUTANEOUS